Business Wire

Juvisé Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY® (ex-US/Canada) and Opens Its Capital to Bpifrance and Pemberton

Share

The French pharmaceutical company, Juvisé Pharmaceuticals, announces the acquisition of global commercial rights (excluding the United States and Canada) to Ponvory® (ponesimod) from Actelion Pharmaceuticals Ltd., a Johnson & Johnson Company (Johnson & Johnson). Ponvory® is indicated for the treatment of adults with active forms of relapsing multiple sclerosis (RMS); it is protected by several patents, the latest of which expires in 2035. To fund this acquisition, the French sovereign fund Bpifrance and Pemberton Asset Management (‘Pemberton’), a leading European private credit manager, have acquired a minority stake in Juvisé Pharmaceuticals. Financial details of these transactions remain undisclosed.

We are very excited about Ponvory® and its potential to have a very positive impact on the lives of patients with multiple sclerosis” announces Frédéric Mascha, founder and President of Juvisé Pharmaceuticals. This acquisition is a strategic step for Juvisé as it expands our portfolio with the first patent protected product with strong development potential over the coming years. It is in line with what we have been doing for the past 16 years, which is providing essential medications to patients and specialist doctors. Following our latest partnerships established with Novartis, AstraZeneca and AbbVie, we are proud to establish a new partnership with a major pharmaceutical company and to have two strong partners such as Bpifrance and Pemberton enter our capital to support our future growth.”

The acquisition of Ponvory®: a strategic move in Juvisé Pharmaceuticals' growth strategy

Multiple Sclerosis (MS) is a chronic autoimmune pathology affecting over 2.5 million patients worldwide and enjoys therapeutic innovation.

Ponvory® (ponesimod) is a first-line treatment option in active forms of relapsing multiple sclerosis (RMS), which is the most common form of the disease (approximately 80% of patients), affecting particularly women around the age of 30-years-old. Ponvory® is the first oral Disease Modifying Treatment (DMT) to demonstrate superior efficacy compared to teriflunomide in a large head-to-head Phase III study (OPTIMUM) in adult patients with active RMS. Ponvory® demonstrated a 30.5% reduction in Annualized Relapse Rate (primary endpoint), as well as reduction in MRI activity and fatigue (secondary endpoints). (1)

Juvisé Pharmaceuticals will leverage its expertise in medical affairs, marketing, and distribution to commercialize and develop Ponvory® outside of the United States and Canada, with a focus on Europe, skills that the company has already demonstrated with the successful European relaunch of Pylera® in 2023. Juvisé Pharmaceuticals will work closely with Johnson & Johnson to ensure a seamless transition and continuous availability of Ponvory® for patients. Ponvory® is currently available in 30 countries, with the objective of expanding this scope. Finally, Juvisé Pharmaceuticals will assume the worldwide manufacturing duties for Ponvory® from sites based in France and Switzerland.

Juvisé Pharmaceuticals opens its capital to Bpifrance and Pemberton

The acquisition of Ponvory® is funded by a mix of capital increase, additional debt, and shareholder loan.

Bpifrance, the French sovereign fund financing businesses in their development, and Pemberton, a leading European private credit manager, have acquired a minority stake in Juvisé as part of the transaction.

About Juvisé Pharmaceuticals

Since its creation in 2008, Juvisé Pharmaceuticals has played a pivotal role in enhancing patient care by providing access to treatments with high medical value. Juvisé re-prioritized essential medicines in oncology (breast and prostate cancer), cardiology, gastroenterology, neuropsychiatry, and rheumatology, making them accessible to over 4.4 million patients every year. Juvisé Pharmaceuticals is present through its products in 80 countries in the world on five continents and relocates the production of its acquired medications in Europe, with 81% being manufactured in Europe and 51% in France. In 2024, Juvisé Pharmaceuticals revenues are expected to reach about 180M€ (+38% vs 2023) with PONVORY® accounting for about 24%.

For more information, visit www.juvisepharmaceuticals.com

Lazard acted as financial advisor to Juvisé Pharmaceuticals and its shareholders.

Bird & Bird, Latham & Watkins and Bredin Prat acted as legal counsel to Juvisé Pharmaceuticals.

Société Générale remains the lead banking partner for Juvisé Pharmaceuticals.

1. Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol. 2021 May 1;78(5):558-567. doi: 10.1001/jamaneurol.2021.0405. PMID: 33779698; PMCID: PMC8008435

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Juvisé Corporate communication contact
Caroline Tranvouez
Chief of staff to the CEO
+33 6 65 20 15 74
caroline.tranvouez@juvise.com

Media Relations contact
Nicolas Delaval
CLAI agency
+33 6 58 29 21 15
juvise@clai2.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Indri Becomes the Fastest Growing Single Malt Brand in the World: Sells Over One Hundred Thousand Cases in Its Second Year12.4.2024 17:09:00 EEST | Press release

Indri, India’s 1st and most awarded triple cask single malt, by Piccadily Distilleries, has further solidified India’s growth story with Indri-Trini becoming the ‘fastest growing single malt in the world ever’. No other single malt brand from Scotland, Japan, Taiwan or anywhere else in the world has ever been able to cross the hundred thousand (100 K) cases mark within two years of its launch. With this feat, Indri-Trini has shattered all expectations and broken into the elite club of top selling single malts in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240412989230/en/ Indri becomes the fastest growing single malt whisky in the world. (Photo: Business Wire) With an unprecedented growth rate of 599% compared to last year, Indri is not just breaking records; it's reinventing the game. Indri has trailblazed its way to capture 30% market share in India. Piccadily Distilleries, with its ambitious expansion plans,

Spiber Inc. Raises Over JPY 10 Billion in Funding to Strengthen Mass Production and Sales Initiatives12.4.2024 10:00:00 EEST | Press release

Spiber Inc. (Director and Representative Executive Officer: Kazuhide Sekiyama; hereinafter “Spiber”), a biomanufacturing startup, is pleased to announce the successful completion of a round of fundraising totaling over JPY 10 billion. This funding, which includes additional investments from existing shareholders, will allow the company to accelerate mass production of its innovative Brewed Protein™ materials and facilitate global sales, further contributing to the advancement of a circular economy. Spiber’s proprietary Brewed Protein™ material is a new category of material¹ developed and refined through more than 15 years of research. By harnessing the diverse, cyclical nature of proteins, one of the key building blocks of Earth’s ecosystem, the company aims to realize a circular economy that can exist in harmony with nature. Using cutting-edge biotechnology, Spiber’s proteins are meticulously designed at the DNA level and manufactured through a proprietary microbial fermentation proce

Jefferies Financial Group Inc. Announces Pricing of €750,000,000 3.875% Fixed Rate Senior Unsecured Notes Due 2026 and €500,000,000 4.000% Fixed Rate Senior Unsecured Notes Due 202912.4.2024 00:28:00 EEST | Press release

On April 9, 2024, Jefferies Financial Group Inc. (NYSE: JEF) (“JFG”, “we” or “our”) priced €750,000,000 aggregate principal amount of 3.875% Fixed Rate Senior Unsecured Notes Due 2026 (the “2026 Notes”) and €500,000,000 aggregate principal amount of 4.000% Fixed Rate Senior Unsecured Notes Due 2029 (the “2029 Notes” and, together with the 2026 Notes, the “Notes”), each under its Euro Medium Term Note Program. The 2026 Notes will mature on April 16, 2026 and the 2029 Notes will mature on April 16, 2029. The offering of the Notes is expected to settle on April 16, 2024, subject to the satisfaction of customary closing conditions. JFG intends to use the net proceeds from the offering of the Notes for general corporate purposes. The Notes have not been and will not be registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release does not and will

Nike Kicks Off Multi-Year Innovation Cycle11.4.2024 21:31:00 EEST | Press release

Today, NIKE, Inc. (NYSE: NKE) extended its position as the undisputed leader of footwear and apparel innovation by debuting a new line-up of products that signaled a multi-year innovation cycle. Brought to life by the full power of digital capabilities and cutting-edge technology, the company is delivering better, faster, more efficient solutions for athletes this summer and opening a world of creative possibilities — including Nike's first sculpted, visible Air Zoom unit in the new Pegasus Premium running shoe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411422311/en/ Harnessing its proprietary Air technology, Nike debuts the Nike Pegasus Premium – taking the cushioning that runners love from the iconic Pegasus franchise and adding Nike’s first sculpted, visible Air Zoom unit. The new, sculpted Air Zoom unit is the brand’s biggest Air innovation since the launch of the Nike Air VaporMax. (Photo: Business Wire) The pro

Contentful Appoints Karthik Rau As CEO11.4.2024 19:00:00 EEST | Press release

Contentful announced today that its Board of Directors has appointed Karthik Rau as the new Chief Executive Officer, succeeding Steve Sloan, who has served as CEO since 2019. Karthik brings more than 20 years of leadership experience to Contentful as a company founder and seasoned operating executive. Most recently, Karthik served as founder and CEO of SignalFx, a cloud monitoring company focused on DevOps teams that was acquired by Splunk for $1.05 billion. Previously, Karthik held several leadership roles in the industry, including Vice President of Product Management and Worldwide Marketing at VMware during its early growth years. Karthik was one of the principal executives who led the VMware IPO, the largest technology IPO of 2007. “Content has become one of the key pillars of every organization’s digital strategy,” said Rau. “The emergence of generative AI will drive exponential growth in content and accelerate the shift from legacy content management systems to Contentful’s marke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye